PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer

•PD-L1 ≥1% is an independent predictor of worse overall survival in resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).•PD-L1 ≥1% is significantly associated with worse disease-free survival regardless of EGFR status.•TP53 co-mutations are more common among PD-L1 ≥1% EGFR-mutated NSCLC.•PD-L1 should be a stratification factor in adjuvant trials for EGFR-mutated NSCLC.